Screening for prostate cancer: Can we learn from the mistakes of the breast screening experience?

European Urology

Volumn 64, Issue 4, 2013, Pages 540-541

  Baum, Michael ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER MORTALITY; CANCER SCREENING; CAUSE OF DEATH; CAUSE SPECIFIC SURVIVAL; EDITORIAL; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RISK FACTOR;

HUMANS; KALLIKREINS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84883786028     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.05.053     Document Type: Editorial

References (4)

1. F.H. Schröder, J. Hugoson, and M.J. Roobol Screening and prostate cancer mortality in a randomised European study N Engl J Med 360 2009 1320 1328
2. M.J. Roobol, R. Kranse, and C.H. Bangma Screening for prostate cancer: results of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer Eur Urol 64 2013 530 539
3. J.A. Lane, F.C. Hamdy, R.M. Martin, E.L. Turner, D.E. Neal, and J.L. Donovan Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies Eur J Cancer 46 2010 3095 3101
4. M. Baum Harms from breast cancer screening outweigh benefits if death caused by treatment is included BMJ 346 2013 f385